Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
ARISTOTLE Objectives • • Primary: test for noninferiority of apixaban, a novel oral direct factor Xa inhibitor, versus warfarin Secondary: test for superiority of apixaban with respect to the primary outcome and to the rates of major bleeding and death from any cause Study Design • • Randomized, multicenter, double-blind, double-dummy 18,201 patients with AF and at least one additional risk factor for stroke, randomized to treatment with apixaban or warfarin Primary Outcome • Ischemic or hemorrhagic stroke or systemic embolism Primary Safety Outcome • Rate of major ISTH bleeding ARISTOTLE Summary of Results • As compared to warfarin, treatment with apixaban in patients with AF and at least one additional risk factor for stroke: – reduces stroke and systemic embolism by 21% – reduces major bleeding by 31% – reduces mortality by 11% • Consistent effects across all major subgroups and with fewer study drug discontinuations on apixaban ARISTOTLE ARISTOTLE Conclusions • In patients with atrial fibrillation, apixaban is superior to warfarin in preventing stroke or systemic embolism, causes less bleeding, and results in lower mortality